Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tysabri in relapsing-remitting multiple sclerosis
NCT01405820Phase 2Completed
- Sponsor
- Biogen
- Start
- Aug 2011
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Aug 2011; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01405820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01405820.